A recent preclinical study indicated that Pinometostat enhances the sensitivity of pediatric AML cells to Sorafenib, a multi-kinase inhibitor, regardless of KMT2A-r status, suggesting that combination therapy with Pinometostat may still hold value in pediatric leukemia [48]. This evidence concerns the gene KMT2A and acute myeloid leukemia.